Chuangyebang was informed that on April 26, Suzhou Wanguiyuan Precision Technology Co., Ltd. (hereinafter referred to as “Wanguiyuan”) announced the completion of tens of millions of A round of financing. This round of financing was led by Dongyun Venture Capital, followed by Qianrong Chuanghe Capital and Sihai New Materials Fund.
Funds from this round of financing will be used to enhance the production capacity of existing product lines, develop new product pipelines, build new production bases and expand R&D teams.
Wanguiyuan is located in Wujiang Economic and Technological Development Zone, Suzhou City. It is an overall engineering solution provider that provides one-stop services for core processes, equipment and solutions for in vitro diagnostic, medical device, life science, and biopharmaceutical enterprises.
Wanguiyuan’s ‘multi-chamber automatic high-speed filling line’ tailored for epidemic prevention and control enterprises has solved the problem of rapid and large-scale demand for epidemic prevention materials. So far, the high-speed lines delivered by Wanguiyuan have accumulated nucleic acid detection. There are more than 50 million reagents, and practical actions are used to help epidemic prevention.
Wanguiyuan has a layout in the fields of biomedicine and high-value medical devices. The existing expanded categories include “high-end wet film automatic production line for sterile environment”, “automatic production base station for neurointerventional devices”, “automatic cell culture production and preparation” and others product line under development.
Mr. Zhang Cangmin, founder of Wanguiyuan, said: With the continuous rapid growth of the life sciences and medical industries, the market demand for high-quality upstream products is increasing. Since its establishment, Wangui has been committed to the research and development and manufacturing of upstream core tools, with a rich and diverse product line, and has the ability to solve a variety of biomedical engineering solutions as a whole. In the future, we will continue to deepen the field of biomedicine, increase talent training, increase investment in innovation and research and development, and help downstream customers’ product core competitiveness.
General Manager Lu of Dongyun Ventures said: As a state-owned investment platform of Suzhou Wujiang Economic and Technological Development Zone, Dongyun Ventures has been committed to finding and investing in high-tech projects in sub-sectors that break through the international blockade for the development zone; Dongyun Ventures has always Committed to the layout of the biopharmaceutical industry chain, it has gradually formed an innovative drug platform, with all-round investment in biological raw materials, IVD, medical devices, and equipment. Completely independent intellectual property rights, and many key technical indicators match or even surpass the performance of world-class products. The company is committed to promoting precision medicine, helping life science and clinical medicine, and expecting the company to continue to innovate in the future, give full play to the performance characteristics and advantages of the platform, and become a global Chinese enterprise with core competitiveness in the overall solution of diverse biomedical engineering solutions , and serve the world.
The representative of Sihai New Materials said: In the field of life science in vitro diagnosis, equipment manufacturers of microfluidic chips and high-value medical consumables are limited by technical barriers, and there are only a handful of companies that can provide a complete set of solutions. It will usher in a situation where a hundred flowers bloom, and as an upstream equipment supplier, it is the booster in this field. During the few years of its establishment, Wanguiyuan has continuously iterated its technology and has withstood the test of the market. It will definitely become one of the leading companies in this field in the future. We look forward to Wanguiyuan’s continuous self-breakthrough and become the backbone of this field.
Qianrong Chuanghe Capital said: At present, the production of in vitro diagnostics and high-value medical consumables is basically manual or semi-automatic. Under the background of centralized procurement, medical production enterprises are facing huge pressure to reduce costs, automation instead of manual labor is the industry. development trend. The medical industry has many subdivisions and high professional barriers. High-end medical automation production lines mainly rely on imports and are expensive. Wanguiyuan’s core team has many years of industry experience and strong ability to solve diverse projects. It has successfully delivered many domestic first sets of automated production lines for industry benchmark customers such as Bohui Innovation, Ustar, Tailin Bio, etc. develop an advantage. We believe that with the continuous expansion of Wanguiyuan’s new product line and the accumulation of delivery cases, the company will develop very rapidly in the future.
media coverage
Investment Community Yiou Venture Capital Investment Community
This article is reprinted from: https://readhub.cn/topic/8fwmZ3ZBqXl
This site is for inclusion only, and the copyright belongs to the original author.